GenPath logo in conjunction with women's health

Prenatal Screening and Diagnostic Testing

ClariTest™ Non-Invasive Prenatal Screening (NIPS)

ClariTest™ harnesses the power of massively parallel sequencing to screen for the most common fetal aneuploidies and specific microdeletion syndromes using a simple blood collection as early as 10 weeks of gestation. Learn more about ClariTest™.

Maternal Serum Screening

GenPath Offerings include a number of blood tests that can provide a risk assessment for Down syndrome, Trisomy 18, and open neural tube defects (ONTDs) to affect a pregnancy. Learn more about maternal serum screening.

Prenatal Diagnostic Testing

GenPath offers many different prenatal diagnostic tests performed on chroinic villus sampling (CVS) and amniocentesis samples.  Learn more about prenatal diagnostic testing.

Combined First Screen

A first trimester test that assesses the risk of Down syndrome and Trisomy 18 using a combination of maternal blood and fetal ultrasound markers. Learn more about the Combined First Screen.

Serum Integrated Screen

A two-part approach that assesses the risk of Down syndrome, Trisomy 18, and open neural tube defects (ONTDs). The screen uses maternal blood markers from the first and second trimesters to provide a combined risk assessment. Learn more about the Serum Integrated Screen.

Integrated Screen

A two-part approach that assesses the risk of Down syndrome, Trisomy 18, and open neural tube defects (ONTDs). This screen uses maternal blood markers from the first and second trimesters in combination with first trimester ultrasound markers to provide a risk assessment. Learn more about the Integrated Screen.

Sequential Screen

A two-part approach that assesses the risk of Down syndrome, Trisomy 18, and open neural tube defects (ONTDs). The components are the same as Integrated Screening; however, initial results are released after the first trimester portion. Final results are released after the second trimester bloodwork is incorporated. Learn more about the Sequential Screen.

Quad Screen

A second trimester screen that assesses the risk of Down syndrome, Trisomy 18, or open neural tube defects (ONTDs) by using maternal serum markers. Learn more about the Quad Screen.

Alpha-fetoprotein (AFP) Screening

A second trimester test that assesses the risk of open neural tube defect by measuring the alpha-fetoprotein level in maternal serum only. Learn more about the Alpha-fetoprotein Screen.

©2019 GenPath, a division of BioReference Laboratories Inc., an OPKO Health Company